Abstract
A total of 4533 isolates from community-acquired respiratory tract infections (CARTIs) and 8446 from skin and skin structure infections (SSSIs) were consecutively collected in 149 US medical centers in 2013. Strains were susceptibility tested by broth microdilution method against ceftaroline and numerous comparators. Ceftaroline (MIC50/90, ≤0.015/0.12μg/mL) was more potent than ceftriaxone (MIC50/90, ≤0.06/1μg/mL) against Streptococcus pneumoniae and highly active against ceftriaxone-nonsusceptible strains (n=201; MIC90, 0.25μg/mL). Ceftaroline was also very active against Haemophilus influenzae (MIC50/90, 0.008/0.015μg/mL), methicillin-susceptible (MIC50/90, 0.25/0.25μg/mL) and methicillin-resistant Staphylococcus aureus (MIC50/90, 1/1μg/mL), and β-hemolytic streptococci (highest MIC, 0.03μg/mL). Ceftaroline exhibited good activity against non–extended-spectrum β-lactamase (ESBL) phenotype isolates of Klebsiella spp. and Escherichia coli (96.7% susceptible and MIC90 of 0.25μg/mL for both) but limited activity against ESBL phenotype isolates. In summary, ceftaroline exhibited potent in vitro activity against a large collection of bacterial isolates causing CARTI and SSSI in US medical centers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
